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Following the mutation screening of genes known to cause
amyotrophic lateral sclerosis (ALS) in index cases from 107
familial ALS (FALS) kindred, a point mutation was identified
in vesicle-associated membrane protein-associated protein B
(VAPB), or VAMP-associated protein B, causing an amino acid
change from threonine to isoleucine at codon 46 (T46I) in one
FALS case but not in 257 controls. This is an important finding
because it is only the second mutation identified in this gene
that causes ALS. In order to investigate the pathogenic effects
of this mutation, we have used a motor neuron cell line and
tissue-specific expression of the mutant protein in Drosophila.
We provide substantial evidence for the pathogenic effects of
this mutation in abolishing the effect of wild type VAPB in the
unfolded protein response, promoting ubiquitin aggregate for-
mation, and activating neuronal cell death. We also report that
expression of the mutant protein in the Drosophilamotor sys-
tem induces aggregate deposition, endoplasmic reticulum dis-
organization, and chaperone up-regulation both in neurons
and in muscles. Our integrated analysis of the pathogenic ef-
fect of the T46I mutation and the previously identified P56S
mutation indicate extensive commonalities in the disease
mechanism for these two mutations. In summary, we show
that this newly identified mutation in human FALS has a path-
ogenic effect, supporting and reinforcing the role of VAPB as a
causative gene of ALS.
Amyotrophic lateral sclerosis (ALS)2 is a common degener-
ative disease, causing muscle weakness and atrophy, paralysis,
and bulbar symptoms, which eventually leads to death due
to respiratory failure within 3–5 years of symptom onset.
ALS is caused by loss of motor neurons, and a characteris-
tic pathological feature of the disease is the presence of
ubiquitinated inclusions containing TDP-43. The mecha-
nism whereby the disease specifically affects motor neu-
rons is unclear, and current therapy is limited in effective-
ness. Major advances have occurred recently with the
identification of mutations causing the familial form of
ALS (FALS), which is clinically indistinguishable from the
sporadic form (SALS), accounts for 5% of cases, and
shares the same pathological features (1). Mutations in
seven genes are known to give rise to FALS, superoxide
dismutase (SOD1), vesicle-associated membrane protein-
associated protein B (VAPB), senataxin, alsin, dynactin,
TARDBP, and FUS, which has shed light on the impor-
tance of oxidative stress, the unfolded protein response
(UPR), protein aggregation, and abnormal RNA processing
in the pathogenesis of ALS (2–5). Multiple mutations have
been described for all of these genes with the exception of
VAPB, where only one missense mutation (P56S) has been
reported to date, being present in seven Brazilian kindred
exhibiting clinically diverse phenotypes, including ALS and
late onset spinal muscular atrophy (6, 7). No other VAPB
mutations have been identified in SALS or other ALS pop-
ulations (8, 9) until now, where we report a second VAPB
mutation and further provide evidence for its pathogenic
effects.
VAPB is a member of the VAP family, which includes
VAPA, an established regulator of vesicle trafficking (10–12).
VAPB plays a role in the UPR, which is activated when mis-
folded proteins accumulate in the endoplasmic reticulum (ER)
(13, 14). VAPs are also known to control lipid metabolism and
lipid transfer between the ER and other organelles by interact-
ing with proteins such as oxysterol-binding proteins (OSBPs),
Nir proteins, ceramide transfer protein (CERT), and Opi1
(15–19). In Drosophila, DVAP-33A (DVAP) controls the
number and size of boutons at the neuromuscular junction.
Furthermore, loss of DVAP disrupts the synaptic microtubule
cytoskeleton (20), causing an increase in miniature junctional
potential amplitudes and postsynaptic glutamate receptor
clustering (21).
In this study, we have demonstrated pathogenic actions of
this novel VAPB mutation, promoting the formation of ubiq-
uitinated aggregates, activating cell death pathways, and lead-
ing to the generation of a robust motor phenotype in vivo in
larval neurons, adult eye, and neuromuscular junction of Dro-
sophila. We have further developed a model of disease
through the integration of our findings with those already
reported for the P56S-VAPB mutation.
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EXPERIMENTAL PROCEDURES
Sequencing—A cohort of 185 FALS kindred was used for
this analysis. Patients and families were referred by general
practitioners and physicians, and the diagnosis of ALS was
carried out according to the El Escorial World Federation of
Neurology criteria for diagnosis of ALS with evidence of both
upper and lower motor neuron involvement. The mean age at
death of patients lacking SOD1 mutations was 55.6 years
(confidence interval (CI), 54.3–56.9 years; n 389) and mean
disease duration was 3.3 years (CI, 2.7–3.9 years; n 193)
(22). In our study, we used 110 FALS cases from this cohort,
where DNA was available, in search of additional mutations in
VAPB. The sequencing reaction was carried out with a total
of 50 ng of DNA and amplified using primers listed in supple-
mental Table S1. PCR products were purified using a Nucle-
ospin extraction kit (Clontech) and eluted in 20 l of molecu-
lar grade water (Sigma). The purified PCR products were
sequenced using a forward or reverse primer and the ABI
PrismTM BigDyeTM terminator kit. DNA sequencing was car-
ried out using an ABI 377 automatic sequencer.
Molecular Cloning of Wild Type and Mutant VAPBs into
GFP and RFP Vectors—To generate the full-length VAPB
fragment, the PCR was performed using 5 and 3 VAPB
primers (GCCAAAGGTGCTCCGCCGC and CTACAAG-
GCAATCTTCCC) with a VAPB template purchased from
OriGene. This fragment was cloned into pcDNA3.1/NT-
GFP-TOPO (Invitrogen) via TA cloning, which produced a
N-terminal GFP fusion protein. For generating the RFP fusion
VAPB, additional restriction enzyme cutting sequences of
EcoRI (GAATTC) and BamHI (GGATCC) were placed at the
5-end of VAPB 5 and 3 primers, respectively. The PCR
product was cloned into pCR2 (Invitrogen) via TA cloning
and then subcloned into pDsRed2-C1 (Clontech) via EcoRI/
BamHI. To introduce the mutations, a traditional two-step
mutagenesis PCR was performed as described in the supple-
mental material. The sequences of all PCR products were ver-
ified by sequencing.
Transfection and Immunocytochemistry—COS-7, N2a, and
NSC-34 cells were cultured in DMEM containing 10% FBS
and were seeded the day before transfection. Cells were trans-
fected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. To establish VAPB-stable expres-
sion cell lines, NSC-34 cells were transfected with either wild
type (WT) or T46I-VAPB and were selected in 10% FBS con-
taining DMEM plus 400 g/ml G418 (Invitrogen).
For western blotting, cells were lysed with radioimmune
precipitation assay buffer, except for the solubility analysis,
which was carried out as described by Kanekura et al. (13).
Protein concentration was determined using the Bio-Rad pro-
tein assay kit. Proteins were separated with 10% SDS-PAGE,
and blotting was carried out using conditions specified for the
antibodies. For immunofluorescence studies, cells were fixed
in 4% paraformaldehyde for 30 min at room temperature and
permeabilized for 30 min in 0.1% Triton X-100 in PBS. Nuclei
were stained with 0.5 g/ml DAPI in PBS for 10 min. PBS
washes were applied between reagent changes. After the final
staining and wash, coverslips were mounted onto slides using
Fluorsave reagent (Calbiochem) and left to dry at 4 °C
overnight.
Antibodies for Immunocytochemistry or Immunofluorescence—
Antibodies used were rabbit polyclonal anti-GFP (1:3000; Ab-
cam), rabbit polyclonal anti-ubiquitin (1:200; Dako), rabbit
polyclonal anti-phospho-eIF2 (1:1000; Cell Signaling), anti-
-actin (1:25000; Sigma), peroxidase-labeled goat anti-rabbit
IgG (1:1000; Vector), and Alexa Fluor 594 goat anti-rabbit IgG
(1:2000; Invitrogen).
Cell Death Analysis—NSC-34 cells were trypsinized,
washed with ice-cold PBS twice, and stained using the an-
nexin V-phycoerythrin apoptotic detection kit (BD Bio-
sciences) according to the manufacturer’s protocol. The cells
were then analyzed with a fluorescence-activated cell sorting
(FACS) flow cytometer (BD Biosciences).
VAPB SNP Typing—DNA was amplified using 20 ng of
genomic DNA, 1.5 mM MgCl2, 0.5 M forward and reverse
primers, 1 PCR buffer, and 1.25 units of Platinum Taq (In-
vitrogen). PCR was performed using 94 °C for DNA denatur-
ing, 58 °C for annealing, and 72 °C for extension. Restriction
enzymes producing different cutting patterns according to
SNP status were used to genotype each SNP. Different size
fragments were then separated by electrophoresis using a 1.5–
2.2% agarose gel. The primer sequences and enzyme used for
each SNP are listed in supplemental Table S2. DNA was ex-
tracted from the aqueous phase of TRIzol homogenates (23)
as described in the supplemental material.
Fly Genetics and Molecular Techniques—Flies were raised
on standard medium at 25 °C. To assess the effect of T48I
mutation in neurons and muscles, UAST48I-DVAP/
UAST48I-DVAP transgenic males were crossed to elav-GAL4
(24) and BG57-GAL4 (25) females, respectively. For tempera-
ture pulses, to induce a higher expression of the GAL4 pro-
tein, flies of the relevant genotypes were left to mate at room
temperature for 24 h, and then the parents were removed, and
the progeny was shifted to 30 °C in a water bath. Site-directed
mutagenesis on DVAP cDNA was performed using the
QuikChange site-directed mutagenesis kit (Stratagene).
Transgenic UAS lines were made by cloning the DVAP cDNA
carrying the T48I mutation into the PUAST vector (26). Con-
structs were injected into the embryonic germ cells, and
transgenic lines were established following standard
procedures.
Cell Transfections and Immunocytochemistry—Full-length
T48I-DVAP and DVAP ORF constructs were generated by
PCR and cloned into Myc- and FLAG-tagged pCMV expres-
sion vectors, respectively. COS-7 cells were cultured in
DMEM containing 10% FCS and 1% penicillin/streptomycin.
COS-7 cells were seeded on poly-D-lysine-coated glass cover-
slips (BD BioCoat) at a concentration of 150,000 cells/ml. The
day after, cells were transfected with transfection reagent
(Roche Applied Science) according to the manufacturer’s in-
structions. 24 h later, cells were fixed in 4% paraformaldehyde
for 20 min and blocked in phosphate-buffered saline contain-
ing 0.1% Triton-x-100 containing 10% normal goat serum.
Staining with the relevant antibodies was performed accord-
ing to the procedure described under “Immunocytochemis-
try.” Rabbit anti-Myc (Sigma) and mouse anti-FLAG (Sigma)
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primary antibodies were used at a concentration of 1:500 and
1:200, respectively. Secondary antibodies (Jackson Immu-
noResearch) were all used at a concentration of 1:500.
Scanning Electron Microscopy and Eye Histology—Eyes
were fixed in 3% glutaraldehyde in 0.1 M sodium cacodylate
buffer, pH 7.3, for 2–3 h and further processed and analyzed
as described in the supplemental material.
Microscopy and Morphological Quantification—To acquire
the two-dimensional images for processing, the bodies were
photographed using a digital camera attached to an Olympus
stereomicroscope and processed as described in the supple-
mental material. Quantification of the eye phenotype was per-
formed using the Oculus version 1.0 software. Oculus version
1.0 is a tool written in MATLAB, which was developed in
house to aid measurement of the size of the adult fly eyes.
Unlike the shape selection tools provided in image processing
software, such as ImageJ (available at the National Institutes
of Health Web site; developed by Wayne Rasband), the Ocu-
lus version 1.0 software presented each image at a zoomed out
level and permitted the border of the eye to be traced pixel-
by-pixel; this method encouraged detailed examination of the
boundary and therefore increased the precision of the delin-
eation. Subsequent automated validation operations ensured
that the highlighted path was closed and skeletonized (27–
29), so the outline could be saved to a data base. The area of
each eye was then measured using a flood-fill operation in
these enclosed regions, and the number of pixels counted was
inserted into a spreadsheet for further analysis.
Immunohistochemistry—Body wall muscles from wonder-
ing third instar larvae were dissected and stained according
to Chai et al. (21). The following primary antibodies were
used: rabbit polyclonal anti-HRP at 1:200 (Jackson Immu-
noResearch), guinea pig polyclonal anti-DVAP at 1:1000
(20), mouse monoclonal anti-KDEL at 1:50 (Stressgene),
mouse monoclonal anti-Hsp70 at 1:200 (Affinity Biore-
agents), rabbit polyclonal anti-SERCA antibody at 1:1000,
and guinea pig polyclonal anti-Boca antibody at 1:1000. For
the co-staining with the anti-Boca antibody, a rat poly-
clonal DVAP antibody was used at 1:1000 (20). Secondary
antibodies (Jackson ImmunoResearch) were all used at a
concentration of 1:500. Fixed and labeled larvae were im-
aged with a Zeiss LSM510 confocal microscope with a 63/
1.4 objective. Single high resolution images were acquired
as stacks of images with separate channels and processed
with the LSM software or Adobe Photoshop and Adobe
Illustrator.
Statistics—A one-way ANOVA test was used to compare
multiple conditions in an experiment. Bonferroni’s multiple
comparison test was used as a post-test when significance was
found in the ANOVA test. In the fly studies, statistical analy-
sis was performed using the two-tailed Student’s t test to
compare the test genotype to controls. Error bars represent
S.E. Single SNP allele frequency and genotype frequency p
values were obtained using the Fisher exact test (see the
Quantitative Skills Web site). The EH program was used to
test linkage disequilibrium between SNPs and to compare the
difference of pairwise haplotype frequency between groups.
The six-SNP haplotype was constructed from the population
genotyping data by the PHASE program (version 2.1),
which also gave a p value of the haplotype frequency differ-
ence between groups (30, 31). BIMBAM was used to evalu-
ate the association between the genotypes and the pheno-
type (32), which, in our case, were SNP haplotype and
VAPB expression level. The Mantel-Haenszel common
odds ratio was obtained from the SPSS statistics package to
evaluate the association of overall major/minor allele with
VAPB expression level. The pathogenicity of the T46I mu-
tation was evaluated using the Web program PMut (33),
which is based on neural networks that have been trained
with a large data base of neutral and pathogenic human
mutations, using predictions of secondary structure and
conservation of sequence (see the Molecular Modelling and
Bioinformatics Group Web site).
RESULTS
Identification of a New ALS-associated Mutation in VAPB,
T46I-VAPB—All six coding exons of VAPB plus flanking in-
tronic regions were sequenced in 107 index cases of FALS
kindred of United Kingdom origin that lacked mutations in
SOD1, TDP-43, and FUS. A point mutation causing an amino
acid change from threonine to isoleucine at codon 46 (T46I)
was identified in one FALS case presenting with typical ALS
but not in 257 healthy controls (Fig. 1A). The index case with
the amino acid substitution in VAPB was diagnosed with clas-
sical ALS. Signs at onset, revealed on first examination at the
age of 73 years, included wasting of the small muscles of the
right hand. There were fasciculations in the left vastus media-
lis and both gastrocnemii. Plantars were flexor. Sensation was
normal, whereas speech and swallowing difficulties developed
at the age of 75 years. The diagnosis was confirmed by nerve
conduction studies. The patient had a brother with ALS who
died within 4 months of diagnosis from bronchopneumonia.
There were no further DNA samples available from this fam-
ily and the patient had no children. DNA was not available
from any other affected members of this family, and this mu-
tation was not found in any of the other FALS cases screened
or in 257 control subjects (Caucasian, which matched the in-
dex case).
Although it was not possible to show transmission of the
mutation with disease due to the lack of DNA samples from
other affected individuals within the family, this mutation is
located within a stretch of 16 amino acids that are highly con-
served across species (Fig. 1, B and C), which also harbors the
P56S mutation that causes ALS8. In support of the impor-
tance of this evolutionarily conserved amino acid, the theoret-
ical pathogenicity of the human VAPB sequence variants pre-
dicted using the program PMut also suggested that T46I was
a pathogenic mutation. The pathogenicity estimate for the
T46I coding change is 0.77 (range is from 0 to 1, where values
0.5 indicate pathogenicity), and the confidence index is 5
(where 0 is a low and 9 is a very high level of confidence). By
comparison, the theoretical pathogenicity of the P56S sequence
variant, found in the Brazilian kindreds, is 0.62 with a confidence
index of 2. Furthermore, extensive sequencing of VAPB has
failed to reveal this mutation in previously screened control pop-
ulations (8, 34) or the control subjects that we sequenced in this
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study.We have therefore carried out a range of functional stud-
ies in cell culture and in vivo to elucidate the potential pathologi-
cal effects of this mutation that it shares with the known ALS-
associatedmutation P56S and to further elucidate novel aspects
of their mechanisms of disease.
Cellular Distribution of T46I and the Formation of Insoluble
Aggregates—Because studies of the ALS-causing mutation,
P56S-VAPB, in cell culture have shown that the mutant pro-
tein forms insoluble cytosolic aggregates and is able to inter-
act with wild type VAPB and VAPA (13, 14, 35), affecting the
function of the WT protein, we tested whether the T46I mu-
tation affected the subcellular distribution and solubility of
the protein. GFP-tagged wild type VAPB (WT-VAPB), T46I-
VAPB, and P56S-VAPB constructs were generated and ex-
pressed in COS-7 cells. The typical ER localization pattern of
a weblike distribution within the cytosol extending from the
nuclear surface was shown for the WT-VAPB construct,
whereas both T46I-VAPB and P56S-VAPB constructs pro-
duced VAPB protein aggregates within cells (Fig. 2A), as re-
ported previously for P56S-VAPB (7, 13, 35). However, there
was greater variance in the distribution of T46I-VAPB, which
showed different degrees of aggregation ranging from small
granules to large coalesced structures with some cells showing
a normal ER distribution. The same distribution patterns
were found following transfection with these constructs in
two neuronal cell lines, the neuroblastoma cell line N2a and
the spinal cord motor neuron cell line NSC-34 (supplemental
Fig. S1). This marked effect on aggregation was also clearly
demonstrated by a shift in distribution from the Triton
X-100-soluble fraction of cell lysates to the insoluble fraction
(Fig. 2, B and C) compared with WT-VAPB, as previously
shown for P56S (13). Although T46I-VAPB showed a differ-
ent impact on VAPB protein distribution when compared
with the P56S mutation, both mutations affected protein solu-
bility to a similar extent (Fig. 2, B and C). This result further
supported the observation that both T46I and P56S mutations
triggered VAPB protein aggregation.
FIGURE 1. Identification of T46I mutation in a FALS family. A, the gene screening identified a point mutation T46I in VAPB. B, Thr46, which is indicated by
an arrowhead, is within the 16-amino acid fragment that is required for VAPB function in yeast, which is highlighted, and is highly conserved in VAP proteins
from yeast to humans. C, sequences of human VAPB (hVAPB) protein and its Drosophila ortholog DVAP were aligned by using the ClustalW version 1.82
alignment program available from EMBL-EBI. Colon, an identity match; period, a conserved substitution according to the GONNET 250 matrix. The predicted
functional domains in both proteins are preserved: a transmembrane domain (green) at the C terminus, a coil-coiled domain (red) in the middle, and a do-
main (gray) at the N terminus showing a significant homology to the nematode major sperm protein (MSP).
FIGURE 2. Protein properties are modified by T46I. A, COS-7 cells were
transfected with the indicated plasmids and fixed 48 h after transfection.
The distribution of VAPB protein is indicated by GFP (green), and nuclei are
shown with DAPI staining (blue). Scale bar, 20 m. B, NSC-34 cells were har-
vested 48 h after transfection with empty GFP vector or GFP VAPBs. The
separation of Triton X-100-soluble and insoluble fraction was carried out as
described by Kanekura et al. (13). The fractions were blotted with anti-GFP
antibody. The densitometry measurements of bands for soluble and insolu-
ble VAPB are shown in C. Values are means S.E. (error bars) for three sepa-
rate experiments.
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T46I-VAPB Is Unable to Activate the IRE1 Pathway—Al-
though VAPB is highly localized to the ER, its actions in ER
function are less well characterized. However, a well docu-
mented function of VAPB is its ability to potentiate the IRE1
pathway, a component of the UPR, which is disrupted by the
P56S-VAPB mutation (13, 14). In order to characterize the
role of VAPB in the IRE1/XBP1 pathway, an XBP1-Venus
construct was used as a reporter of IRE1/XBP1 activation
(36). Under normal conditions, the mRNA for the transcrip-
tion factor, XBP1, contains a premature stop codon and thus
produces an immature protein with a short half-life. When
cells are under ER stress, the activated IRE1 causes the splic-
ing of XBP1 mRNA into a mature mRNA, which in turn pro-
duces the functional transcription factor. Based on the nature
of this alternative RNA splicing, Iwawaki et al. (36) developed
an ER stress reporter by fusing a fluorescent protein, Venus,
to XBP1, which can only be expressed when the IRE1-medi-
ated splicing takes place. Thus, the presence of the fluores-
cence indicates the activation of IRE1.
RFP-tagged WT-VAPB, T46I-VAPB, and P56S-VAPB con-
structs were generated and co-transfected with the XBP1-
Venus reporter into NSC-34 cells. The presence of the re-
porter in RFP-positive cells was quantified for each construct
using flow cytometry. Further, the effect of WT and mutant
VAPBs on the response to the ER stress inducer, tunicamycin,
which is known to inhibit N-linked glycosylation, was also
investigated.
WT-VAPB showed a clear induction of IRE1 activity, in-
creasing 9-fold above the vector control after 24-h transfec-
tion, an effect that was enhanced in the presence of tunicamy-
cin (ANOVA, p 0.001 and 0.0035, respectively; Fig. 3, A and
B). This property was significantly impaired in both T46I- and
FIGURE 3. VAPB participates in the UPR. NSC-34 cells co-transfected with XBP1-Venus and RFP VAPB without (A) or with tunicamycin treatment (2 g/ml,
treated for 6 h before harvested) (B). RFP- and Venus-positive cells were quantified by FACS. The proportions as a percentage of Venus-positive cells in RFP-
expressing cells are shown. C, cells stably expressing wild type or T46I-VAPB were transfected with Venus and RFP constructs. 24 h after transfection, cells
were harvested and analyzed as in A and B. The p values from one-way ANOVA are 0.001 (A), 0.0035 (B), and 0.0417 (C), respectively. Bonferroni’s multiple
comparison test was applied as a post-test, and the significance values are shown in the graphs. D and E, the level of phosphorylated eIF2was examined in
transiently transfected cells (D) and in VAPB-stable expression cell lines (E) with or without thapsigargin treatment (500 nM for 30 min before harvest). After
correcting with the loading control, actin, the level of phosphorylated eIF2was quantified. All experiments were repeated at least three times. Values are
means S.E. (error bars). *, p 0.05; **, p 0.01; ***, p 0.001.
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P56S-VAPB-expressing cells (p 0.001; Fig. 3A). The inhibi-
tory effect of T46I was stable, yielding a reduced activation
(50%) at 48 h after transfection, compared with WT-VAPB
(p 0.05). Upon tunicamycin treatment, a partial response
was seen with T46I-VAPB, but this was not significant.
In a second series of experiments, we used NSC-34 perma-
nent cell lines stably expressing WT-VAPB or T46I-VAPB
protein transfected with a RFP-VAPB expression construct
and XBP1-Venus to determine whether mutant VAPB inter-
fered with the ability of WT-VAPB to activate this pathway.
Although the expression of WT-VAPB in this stable cell line
substantially induced IRE1/XPB1 activation, transfection with
WT-VAPB significantly increased the magnitude of Venus
induction (Fig. 3C). However, in T46I-VAPB-stable cells,
transfection with WT-VAPB was not able to induce IRE1/
XBP1 activation (Fig. 3C), which indicated that endogenous
T46I-VAPB may interact with and prevent exogenously ex-
pressed WT-VAPB from promoting IRE1/XBP1 activation.
Taken together, these results suggested that T46I-VAPB not
only lost the ability to activate IRE1 pathway efficiently but
also was able to inhibit the action of the wild type protein.
The activation of another ER stress sensor present in the
ER membrane, PERK, was also investigated. This pathway is
involved in the regulation of translational suppression and the
induction of certain ER chaperone proteins, which are medi-
ated in part through the phosphorylation of eIF2 (37). We
monitored the phosphorylation of eIF2 in response to the
fast acting ER stress inducer thapsigargin, which acts by in-
creasing cytosolic calcium concentration through inhibiting
intracellular calcium pumps (supplemental Fig. S2), and com-
pared the response of VAPB-expressing cells with those of
untransfected and vector-transfected cells (Fig. 3, D and E).
However, phosphorylation of eIF2 was not significantly
modified in the presence of either wild type or mutant
VAPBs, using either transiently transfected or permanent cell
lines (Fig. 3, D and E). Taken together, these data show that
VAPB protein activates the unfolded protein response by act-
ing through the IRE1/XBP1 pathway and that the VAPB pro-
tein containing the newly identified T46I mutation lacks this
property.
Ubiquitin Aggregation Is Triggered by Mutant VAPB—The
presence of ubiquitin-positive aggregates is a widely used
marker of the progression of neurodegenerative diseases,
which occurs in ALS and the G93A-SOD1 mouse model of
ALS. To investigate whether the expression of mutant VAPB
triggered the formation of ubiquitin-positive aggregates,
NSC-34 cells were transiently transfected with GFP-VAPB
constructs and immunostained for endogenous ubiquitin, and
cells containing ubiquitin-positive aggregates were quantified
for each genotype. Ubiquitinated aggregates were abundant in
both T46I- and P56S-VAPB-expressing cells compared with
WT-VAPB-expressing cells, whereas GFP-transfected cells
contained few or no aggregates (Fig. 4A). A similar increase in
the proportion of cells expressing either T46I or P56S-VAPB
compared with WT-VAPB was observed (ANOVA, p
0.0047) (Fig. 4B). The number of ubiquitin-positive cells ex-
pressing WT-VAPB was similar to that seen in the vector
control (Fig. 4B).
Previous studies of mutant SOD1 have suggested that a
non-cell-autonomous effect occurs, which may be a conse-
quence of secretion of the mutant protein (38, 39), and in or-
der to determine whether this is relevant to VAPB, which is
known to be secreted in a truncated form in Drosophila (21,
40, 41), we also analyzed the effect of VAPB-expressing cells
on the formation of ubiquitinated aggregates in the neighbor-
ing GFP-negative cells. Indeed, we found a significant effect
due to T46I-VAPB (ANOVA, p 0.022) (Fig. 4C), which sug-
gests that mutant VAPB-expressing cells secrete a factor that
FIGURE 4.Mutant VAPB induces ubiquitin aggregate formation in bothmutant protein-expressing and neighboring cells. A, 3 days after transfection
with either vector or GFP-VAPBs constructs, NSC-34 cells were fixed and stained for endogenous ubiquitin. Examples of ubiquitin aggregates are indicated
with arrows in each section. Ubiquitin aggregates found in GFP-negative cells are also pointed out with open arrowhead. The number of GFP-positive cells
(B) and GFP-negative cells (C) containing ubiquitin aggregates was counted for three independent transfections. The p values from one-way ANOVA test are
0.0047 and 0.022, respectively. Bonferroni’s multiple comparison tests were applied as a post-test, and the significance is shown in the graphs. Values are
means S.E. (error bars). *, p 0.05; **, p 0.01.
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can influence these neighboring cells. A similar non-signifi-
cant trend was seen for P56S-VAPB-expressing cells (Fig. 4C).
No VAPB protein was detected in the culture medium from
the mutant transient transfections (data not shown), in agree-
ment with a previous study (40). Although non-cell-autono-
mous toxicity appears to be relevant to a number of CNS dis-
eases, whether secreted mutant VAPB is involved in ALS
pathogenesis remains to be elucidated.
We further investigated whether the expression of exoge-
nous GFP-VAPBs affected the distribution of endogenous
VAPB in untransfected neighboring cells using a VAPB an-
tibody provided by Dr. Lev (15). Expression of endogenous
VAPB was detected in NSC-34 cells although present at a
much lower level than overexpressed GFP-labeled VAPBs.
However, we could detect no evidence that mutant VAPB
expressed in the neighboring cells affected the distribution
of endogenous VAPB in untransfected cells (supplemental
Fig. S3).
In summary, these data show that T46I-VAP induces the
formation of ubiquitinated aggregates. Surprisingly, a signifi-
cant increase in the ubiquitin-positive clusters was observed
in untransfected neighboring cells, suggesting a possible non-
cell-autonomous effect of the mutant protein-expressing cells
on surrounding cells.
In order to investigate whether the accumulation of cellular
ubiquitinated aggregates was caused by impaired proteasome
activity, we measured the effect of the T46I-VAPB mutation
on the activity of the ubiquitin-proteasome system (UPS) in
VAPB-expressing cells. Using the UPS reporter GFP-CL1,
which leads to an accumulation of GFP in cells with UPS im-
pairment (42), our preliminary results indicate that protea-
some activity is impaired in cells expressing T46I-VAPB,
whether transiently transfected or permanent cell lines (sup-
plemental Fig. S4).
The Expression of T46I-VAPB Leads to Cell Death—Al-
though the UPR initially plays a cytoprotective role, when the
stress is prolonged, a switch from this prosurvival program to
a proapoptotic program occurs in which a number of pro-
apoptotic proteins, such as caspase-12 (rodents) and
caspase-4 (humans), are activated, leading to cell death (37).
We therefore investigated whether the presence of mutant
VAPB proteins activated apoptosis by measuring the appear-
ance of both early and late apoptotic markers. We first looked
at the presence of annexin V on the cell membrane, an early
apoptotic marker, using permanent cell lines. A marked in-
crease in the number of annexin V-positive cells expressing
T46I-VAPB compared with cells expressing the WT protein
was found, as shown by the flow cytometry profiles (Fig. 5A).
When quantified, this increase was highly significant (Fig. 5B).
We also examined the appearance of 7-AAD, a late apoptotic
marker. In this case as well, we observed that the expression
of the mutant protein was accompanied by a significant in-
crease in the number of 7-AAD-positive cells when compared
with cells expressing WT-VAPB (Fig. 5B, p 0.0045). T46I-
VAPB-induced apoptosis was further shown to be caspase-de-
pendent because the treatment of benzyloxycarbonyl-VAD
efficiently reduced mutant VAPB-induced cell death (supple-
mental Fig. S5). In contrast, inhibition of caspase-12 has no
effect (supplemental Fig. S5). Caspase-12, which is acti-
vated downstream of the IRE1/XBP1 pathway, is believed
to be involved in ER stress-induced apoptosis (43). Because
mutant VAPB is unable to activate IRE1/XBP1, it is not
surprising that mutant VAPB-induced apoptosis is
caspase-12-independent.
In order to assess the effect of the mutant protein on WT-
VAPB, a co-culture was set up, in which the permanent cell
line expressing WT-VAPB was co-cultured with the same
number of cells expressing T46I-VAPB. The total number of
cells in the co-culture was the same as that in the single cul-
tures (total of 3,000 cells in each condition). Although only
half of the cells in the co-culture expressed T46I-VAPB, a sig-
nificantly increased number of annexin V-positive cells were
detected (ANOVA; p 0.0004; Fig. 5C). This suggested that
T46I-VAPB interacted with WT-VAPB, promoting apoptosis.
Transgenic Expression of the Mutant Protein in Drosophila
Larval Neurons Induces the Formation of Aggregates—In or-
der to gain further insight into the effect of the T46I-VAPB
mutation in ALS pathogenesis, we turned to Drosophila, an
organism proven to provide a model for VAP-induced ALS
(21, 40, 41). The threonine at position 46 in humans corre-
sponds to threonine at position 48 in Drosophila VAP (T48I-
FIGURE 5. The expression of T46I-VAPB leads to a greater level of cell
death. NSC-34 cells that stably express either wild type or T46I-VAPB were
harvested for annexin V and 7-AAD staining after 3 days of culture. A, a
representative experiment demonstrating the use of FACS to quantify
the annexin V-positive cells. The gating of annexin V-positive cells and
the percentage the gated cells are displayed. B, the annexin V- and
7-AAD-positive cells from four experiments were quantified. The p val-
ues from unpaired t test are 0.0038 and 0.0315 for annexin V and 7-AAD,
respectively. C, a total of 3,000 cells were plated in each condition,
whereas equal amounts of wild type- and T46I-VAPB-expressing cells
were seeded in the co-culture. Cells were harvested and stained for an-
nexin V 3 days after plating. Values are means  S.E. (error bars) for three
separate experiments. The p value from the one-way ANOVA test is
0.0004, and Bonferroni’s multiple comparison test was applied as a post-
test. *, p  0.05; **, p  0.01; ***, p  0.001.
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DVAP) (Fig. 1C). DVAP cDNA containing the T48I mutation
was generated by site-directed mutagenesis and subcloned
into Drosophila transformation vectors (UAST48I-DVAP).
Several independent transgenic lines were established, and
the mutant transgenes were expressed by using the UAS/
GAL4 system (26). In Drosophila, the UAS/GAL4 system al-
lows the temporal and tissue-specific expression of a trans-
gene by using a variety of GAL4 drivers (26). We targeted the
expression of UAST48I-DVAP in larval neurons by using the
pan-neural driver elav-GAL4 (24).
Because VAPB aggregates have been clearly demonstrated
for this mutation in cell culture (see above) and for the P56S
mutation in flies (21), we assessed whether the accumulation
of inclusions containing the protein causing the disease is also
common to T48I-DVAP-induced pathology. We performed
confocal analysis on larval brains and nerve fibers of T48I-
DVAP transgenic larvae stained with antibodies specific for
DVAP. In WT flies, DVAP is distributed underneath the cell
membrane and in the cytoplasm of neuronal cell bodies (Fig.
6, A–C), where an extensive co-localization with ER-specific
markers is observed (Fig. 6, D–F). In contrast, neurons of
transgenic larvae expressing T48I-DVAP are filled with
brightly fluorescing inclusions of variable sizes (Fig. 6, G and
H). In control nerves, VAP immunoreactivity is uniformly
distributed, whereas in T48I-DVAP nerves, numerous mas-
sive aggregates are visible (Fig. 6, compare I and J). This phe-
nomenon was consistently observed in all transgenic lines
examined. Conversely, several lines expressing the WT-DVAP
protein at similar or higher levels do not show the formation
of aggregates (data not shown) (21). Taken together, these
data indicate that transgenic expression of DVAP-T48I in
neurons induces the formation of intracellular inclusions
brightly immunoreactive for DVAP.
Targeted Expression of T48I-DVAP in the Adult Eye Causes
Neuronal Degeneration—To assess the potential role of T48I-
DVAP toxicity in neurons other than motor neurons, we tar-
geted the expression of T48I-DVAP in the nervous system of
adult flies. This would allow us to study the progression of the
phenotype on the temporal axis because the life span of an
adult fly is much longer than that of a larva. When the T48I-
DVAP transgene was expressed into the adult brain by using
the elav-GAL4 driver, flies of the correct genotype failed to
hatch. This early death phenotype is consistent with a severe
loss of integrity of the nervous system. We then targeted the
expression of T48I-DVAP transgene in the eye using the eye-
less-GAL4 driver because adult vision is not required for via-
bility (44, 45). T48I-DVAP transgenic lines exhibited an ab-
normal eye phenotype upon eclosion. As compared with
controls, the eyes expressing the T48I-DVAP transgene were
reduced in size and displayed a rough phenotype over the en-
tire surface. Analysis using scanning electron microscopy re-
vealed disorganized and fused ommatidia with missing, irreg-
ular, and occasional supernumerary mechano-sensory bristles
(Fig. 7, A–D). Paraffin sections of the heads of T48I-DVAP
transgenic flies confirmed the loss of cells beneath the exter-
nal surface of the eyes. Photoreceptor morphology was se-
verely disrupted, and several vacuoles were visible (Fig. 7, E
and F). Vacuolization has been observed in several fly models
of neurodegenerative diseases, and the appearance of these
vacuoles has been correlated to neurodegeneration (46–48).
Another important aspect of the T48I-DVAP-induced eye
phenotype seen in adult flies is the fact that the size of the eye
exhibits a significant degree of heterogeneity in the severity of
the phenotype. We performed a detailed quantification of the
eye size in both mutants and controls by using Oculus version
1.0, a MATLAB software recently developed in our laboratory
(see “Experimental Procedures” for a detailed description of
this software). The distribution of the eye size was measured
over a cohort of at least 25 flies carrying the T48I-DVAP
transgene. Eye sizes from a similar number of control flies
were also measured. The majority of the mutant flies (65%)
possessed eye sizes between 1000 and 2000 arbitrary square
units, whereas the remaining flies exhibited a larger size rang-
ing between 2000 and 2500 square units. Control flies on the
other hand have eye sizes centered between 4000 and 4750
FIGURE 6. Targeted expression of T48I-DVAP in neurons induces the
formation of aggregates immunoreactive for DVAP. A–C, neuronal cell
bodies of WT larval brains immunostained with an anti-DVAP antibody (red)
and anti-HRP antibody (green), a neuronal cell surface marker. DVAP is lo-
cated underneath the cell membrane and in the cytoplasm. D–F, immuno-
staining with an anti-KDEL antibody, an ER-specific marker, shows that the
cytoplasmic DVAP immunoreactivity associates with the ER. G–J, brains and
nerve fibers of third instar larvae stained with antibodies for DVAP (red) and
with antibodies for the neuronal cell surface marker anti-HRP (green). In
controls (G), DVAP staining appears dispersed throughout the cytoplasm of
neuronal cell bodies, whereas in T48I-DVAP transgenic brains (H), DVAP im-
munoreactivity is associated with intracellular aggregates of variable size.
Nerve fibers of control larvae (I) and transgenic larvae (J) were stained with
anti-HRP (green) and anti-DVAP antibodies (red). In control nerves, a faint
and uniform staining for DVAP is observed, whereas in transgenic nerves,
large aggregates strongly immunoreactive for DVAP accumulate along the
nerves. Scale bars, 20 m (J) and 10 m (C, F, and H).
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square units (Fig. 7, G and H). Overall, the eye size in T48I-
DVAP transgenic flies is less than 50% of the size of controls
(Fig. 7H, p 0.0001).
Although the accumulation of aggregates strongly immu-
noreactive for T48I-DVAP was evident in transgenic animals
expressing the mutant protein in neurons (Fig. 6), the pattern
of expression of the WT protein was no longer detectable
(Fig. 6, compare G with H and compare I with J). To test
whether the mutant protein can recruit the WT protein into
the aggregates, we co-transfected COS-7 cell lines with plas-
mids encoding a FLAG-tagged version of DVAP and a
MycT48I-DVAP plasmid. The subcellular localization of both
proteins was determined by using tag-specific antibodies. In
COS7 cells transfected with DVAP, the protein forms a pe-
rinuclear reticular staining, as expected for an ER-associated
protein (Fig. 8A). When COS-7 cells were cotransfected with
both FLAG-DVAP and MycT48I-DVAP, a diffuse punctate
staining reminiscent of the aggregates present in cell bodies
and motor fibers of T48I-DAVP transgenic larvae, was ob-
served (Fig. 8, B–G). Interestingly, the staining of the WT and
the mutant proteins perfectly overlap, indicating that both
proteins are components of the intracellular inclusions
(Fig. 8, B–G).
Transgenic Expression of T48I-DVAP in Larval Brains
Causes ER Fragmentation and Heat Shock Protein
Up-regulation—As reported above for the expression of the
mutant protein in motor neuron cell lines, expression of the
same protein in Drosophila neurons induces cell degeneration
and accumulation of aggregates both in cell bodies and in
nerves. We also showed that the accumulation of misfolded
proteins in the aggregates triggers a UPR response in cell
culture. In Drosophila, the UPR pathway is not well charac-
terized due, at least in part, to the fact that the UPR genes
are essential during development (49). We therefore inves-
tigated whether other neuropathological features that are
usually associated with the UPR response were present in
our fly model.
The presence of aggregates in the form of intracellular in-
clusions containing the disease-causing protein is thought to
arise from the unfolding or misfolding of the same protein.
Protein folding occurs in the cytoplasm or within the lumen
of the ER. In the ER a specialized set of chaperones and com-
ponents of quality control machinery ensures correct folding.
Interestingly, structural abnormalities in the ER characterized
by ER fragmentation and Golgi cisternal dilation have been
reported in motor neurons of brain stem and spinal cord of
patients affected by sporadic ALS (50). To assess whether
such a neuropathological feature is also common to T48I-
DVAP-induced ALS, we stained T48I-DVAP transgenic
brains with an anti-KDEL antibody, a marker specific for ER-
resident proteins. In controls, the anti-KDEL staining detects
a reticular, perinuclear pattern, as expected for a marker high-
lighting the ER (Fig. 8, H–J). In transgenic brains, the staining
appeared fragmented and dispersed throughout the cell (Fig.
8, K–M). Occasionally, the staining was found to co-localize
with the aggregates immunoreactive for DVAP (data not
shown). This phenotype was confirmed by using an antibody
specific for the Boca protein (51), another independent ER
marker (supplemental Fig. S6).
Affected tissues in neurodegenerative diseases often exhibit
the induction of a chaperone stress response. Heat shock pro-
tein induction has been reported in a mouse model with wide-
spread mutant SOD1 expression (52), and chaperones have
been found to be associated with SOD1 inclusions in motor
neurons (52–54). Recent data suggest that up-regulation of
FIGURE 7. Transgenic expression of T48I-DVAP in the adult fly eyes
causes a severe disruption of eyemorphology. A and B, scanning elec-
tron micrographs of controls (A) and transgenic adult fly eyes expressing
the UAST48I-DVAP transgene under the control of the eye-specific driver,
eyeless-GAL4 (B). C and D, higher magnifications of A and B, respectively.
Whereas the adult Drosophila eye is composed of an ordered array of om-
matidia and interspersed bristles, transgenic eyes appear smaller, with miss-
ing or extra bristles and fused ommatidia. Fused ommatidia are indicated
by awhite arrowhead, whereas a black arrowhead points to ommatidia with
extra bristles. Thewhite arrow points to missing bristles. Frontal sections of
fly heads of control animals (E) and from flies expressing T48I-DVAP in the
eye (F) are shown. Transgenic eyes show a severely disrupted internal mor-
phology, cell degeneration, and numerous vacuoles (see arrowheads, for
instance). G, summary of the relative frequency of eye sizes for WT and
transgenes. H, quantification of the eye surface area showing that in trans-
genic flies expressing T48I-DVAP in the eye, the surface area is, on average,
50% smaller than controls. Scale bars, 200 m (A and B) and 100 m (C and
D). Error bars, S.E.
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Hsp70 is beneficial to disease progression in mouse models of
ALS (55). Brains of transgenic larvae expressing T48I-DVAP
were stained with an anti-Hsp70 antibody. In control brains,
Hsp70 staining was faint and spread throughout the cyto-
plasm of neurons, whereas in the transgenic brains, clusters of
specific immunoreactivity were observed. These clusters are
closely associated but do not overlap with DVAP aggregates
(Fig. 8, N–S). In summary, as already reported for the first
P56S-DVAP fly model (21, 40, 41), targeting the expression of
T48I-DVAP in neurons induces aggregate formation, cell de-
FIGURE 8. Transgenic expression of T48I-DVAP induces formation of aggregates composed of wild type andmutant proteins, ER fragmentation,
and Hsp70 up-regulation. A–G, COS7 cells transfected with DVAP-FLAG (A) or FLAG-DVAP and MycT48I-DVAP (B–G) were stained with antibodies specific
for the two tags. H–M, brains from control (H–J) and T48I-DVAP transgenic (K–M) larvae were stained for the ER marker, KDEL (green), and DVAP (red).
N–S, brains from control (N–P) and T48I-DVAP transgenic (Q–S) larvae were stained for DVAP (red) and Hsp70 (green). Scale bars, 10 m.
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generation, ER fragmentation, and up-regulation of chaper-
one proteins.
The Skeletal Muscle Is a Direct Target of T48I-DVAP-medi-
ated Toxicity—The advantage of using an intact organism as a
model for human diseases is that it allows the study of the
effect of a pathogenic mutation in different cell types. Alter-
ations in skeletal muscles during ALS have been considered to
result from toxicity of the mutant protein in motor neurons
rather than a direct effect of the same protein on muscle cells.
In order to explore whether skeletal muscle is a direct target
for T48I-DVAP-mediated toxicity, we generated transgenic
flies in which the DVAP mutant gene was selectively ex-
pressed in skeletal muscles. To this end, the BG57-GAL4 line
was used because GAL4 expression in this line is under the
control of a muscle-specific enhancer (56). We first assessed
the presence of DVAP in larval skeletal muscles and its spe-
cific subcellular localization within the muscle. Dissected neu-
romuscular junctions were stained with a range of muscle-
specific markers. As expected from previous studies, we
observed DVAP immunoreactivity to be distributed through-
out the cytosol of the muscle (35, 57). The staining appears to
be concentrated around the nuclei of the muscle syncytium
largely co-localizing with SERCA, a calcium ATPase, associ-
ated with the sarcoendoplasmic reticulum of the muscle (58)
(Fig. 9, A–F).
As already observed for transgenic expression of the mu-
tant allele in neurons, the expression of the same protein in
muscles using BG57-GAL4 driver, induced the formation of
large aggregates strongly immunoreactive for DVAP (Fig. 9, K
and Q). In the same lines, fragmentation of the ER was also
observed when the transgenic flies expressing T48I-DVAP
specifically in muscle were stained with an antibody specific
for Boca, an ER marker in Drosophila (51) (Fig. 9J). In con-
trols, however, anti-Boca staining of muscles exhibited a retic-
ular and perinuclear pattern (Fig. 9G). Interestingly, immuno-
staining of transgenic muscles with both anti-DVAP and
anti-Boca antibodies showed that DVAP-positive aggregates
extensively colocalize with the fragmented ER (Fig. 9L). This
phenotype was confirmed by using SERCA, another inde-
pendent ER/sarcoplasmic reticulum marker (data not shown).
In many neurodegenerative diseases, including ALS, aggre-
gates are thought to be formed from the accumulation of mis-
folded proteins that trigger the up-regulation of chaperone
proteins. We assessed whether this was also the case for mus-
cles expressing T48I-DVAP. In controls, Hsp70 protein is
very low and almost under the detection limit of our antibody
(Fig. 9,M–O). In transgenic animals expressing T48I-DVAP
specifically in skeletal muscles, there is an increase in the ex-
pression levels of Hsp70 that appears to concentrate in puncta
mainly localized to the nucleus (Fig. 9, P–R). Although the
phenomenon of relocation of Hsp70s to the nucleus is still
poorly understood, it is clear that this relocation is directly
linked to cellular stress (59, 60). Similar results were observed
when a P58S-DVAP transgene expressing the other DVAP
mutation causing ALS8 in humans was targeted to the muscle
using the BG57-GAL4 driver (data not shown).
Genotype Correlations with VAPB Expression in SALS—In
view of our previous observation that the expression of VAPB
is significantly decreased in SALS spinal cord compared with
controls (23), we investigated whether VAPB SNP variants
were associated with the level of expression of VAPB in spinal
cord in this large cohort of cases described previously (23).
Because there are no reported functional SNPs in the coding
region or splice sites, we chose SNPs that are close to exon
boundaries, which might also detect uncharacterized func-
tional variants. The six SNPs selected for this study were
rs6026230T/C, rs6026256T/G, rs2234487C/G, rs2234489G/A,
FIGURE 9.Muscle-specific expression of T48I-DVAP causes cellular
stress characterized by aggregate deposition, fragmentation of the
sarcotubular system, and Hsp70 up-regulation. A–F, body wall muscle
fibers from control larvae were stained for SERCA (green), as ER-sarcoplas-
mic reticulummarker and DVAP (red). A higher magnification of a smaller
area is shown in D–F, demonstrating a high degree of overlap. G–L, control
(G–I) and transgenic (J–L) muscles were stained for DVAP (red) and the ER
marker, Boca (green).M–R, control (M–O) and transgenic (P–R) muscles were
stained for DVAP (red) and the Hsp70 (green). Scale bars, 10 m.
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rs6100067C/T, and rs1802459A/G, and their locations within
the gene are shown in Fig. 10A. A total of 63 samples composed
of 21 healthy controls and 42 ALS were genotyped and divided
into normal (n 36) and low (n 27) expression groups. Nor-
mal levels of expression were defined by the 90% CIs of the con-
trol group, which contained 19 of 21 of control cases. 60% of the
ALS cases were outside this CI. Two groups were formed using
this threshold; group 1 contained samples with normal expres-
sion (90% CI of control group), and group 2 contained samples
with low expression and was composed of 27 samples, including
24 SALS, 1 FALS, and 2 controls.
A significant difference in allele frequency for SNP
rs6100067 was found between normal and low VAPB expres-
sion (Fig. 10B) using both the Fisher exact test (p 0.029)
and the BIMBAM program (p 0.026). The rare allele was
more abundant in the group with normal VAPB expression
levels compared with the group with low VAPB expression
levels, which suggests that this SNP has a beneficial effect pre-
venting decreased VAPB gene expression. Although no signif-
icant association was found between expression levels and the
other SNPs per se, there was a consistent trend in which the
rare allele frequencies of all six SNPs were lower in the low
VAPB-expressing samples compared with the normal ex-
pressing group (Fig. 10B). Indeed, a significant linkage was
found using the Mantel-Haenszel test, which indicates that
these six VAPB SNPs show an overall association of major
allele with VAPB low expression (p 0.0001; Mantel-Haens-
zel common odds ratio 2.04). The two-SNP haplotype was
then constructed and examined by the EH program, and only
the rs6026230-rs6100067 haplotype was found to be signifi-
cantly different between the two expression groups (p
0.047), where the C-T haplotype was decreased by 14% in the
low expression group. The population-attributable risk (61) of
disease associated with low expression of VAPB mRNA is
50.79% (p  5.4  105), of which the fractional change in
VAPB expression attributable to the minor allele
rs6100067 is 18.98% (p  0.02). This equates to an overall
protective effect of 9.6% for the minor allele. Despite the
fact that this SNP has no known function and is outside
regulatory regions involved in RNA splicing, it may
be linked to a functional sequence variant that is responsible
for the VAPB expression difference.
DISCUSSION
In this study, we report the identification of a novel muta-
tion in VAPB, which is not only the second mutation in VAPB
to be found associated with FALS but is the first to be found
in a non-Brazilian kindred. Although it was not possible to
show transmission of the mutation with disease due to the
lack of availability of additional DNA samples within the fam-
ily and the late onset of disease in the index case, we have ob-
tained extensive evidence for the pathogenicity of the T46I-
VAPB mutation based on functional studies in cell culture
and in vivo. Calculation of the theoretical pathogenicity of
this mutation, which is greater than that of the P56S-VAPB
mutation, provides additional support. Furthermore, exten-
sive sequencing of VAPB has failed to reveal this mutation in
control populations (8, 34) (this study).
Evidence for the pathogenic effect of this mutation is pro-
vided using motor neuron cell lines and motor system-tar-
geted expression in Drosophila. We have shown for the first
time that mutant VAPB causes cell death and that this T46I
mutant protein in turn affects neighboring cells that do not
express the mutant protein. Furthermore, we previously re-
ported a substantial down-regulation of VAPB mRNA in
SALS spinal cord (23), and in this study we have shown a SNP
association with levels of expression, suggesting that VAPB is
widely involved in ALS pathogenesis, which is further borne
out by studies in G93A-SOD1 transgenic mice (35).
VAPB and ER Stress—ER stress is a well established feature
of ALS (1, 62), and the discovery of ALS-associated mutations
in VAPB, a key component of this response, highlights the
importance of this essential response in neuronal survival.
Early studies showed that the yeast homolog VAP, Scs2, re-
stored inositol auxotrophy IRE1/Hac1 mutant cells (63, 64),
which implies a role for VAP in lipid transfer and/or synthesis
and sheds light on the cross-talk between VAP and IRE1/
XBP1.The latter was also verified in mammalian systems,
where VAPB triggers the cleavage of XBP1, an initial signal
for IRE1 activation (13, 14). The ALS-associated mutations in
VAPB, T46I and P56S, abolish the ability of WT-VAPB to
activate IRE1/XBP1, as shown in this study. Furthermore,
both P56S-VAPB and T46I-VAPB cause a redistribution of
wild type protein, trapping it in VAPB inclusions in mamma-
lian cells and Drosophila (this study) (21, 40), and due to their
tendency to form heterodimers with WT-VAPB, they may
also prevent WT-VAPB from fulfilling its role during the UPR
(13, 14). The results presented here support the hypothesis
that affected motor neurons fail to activate a functional UPR
to counteract ER stress, which, if prolonged, leads to cell
death (Fig. 11).
FIGURE 10. The rare allele frequency comparison between normal and
low VAPB expression groups. A, the positions of the six SNPs within the
VAPB gene are shown. The whole VAPB gene, containing six exons (repre-
sented with filled boxes), spans to 57.5 kb. Five SNPs closest to each exon
and one in the 3-UTR (represented with an open box) were genotyped.
B, the rare allele frequencies of the six SNPs are shown where the normal
VAPB expression group is represented as filled bars, and the low VAPB ex-
pression group is represented with open bars. The group with normal VAPB
expression level is composed of 16 SLAS, 1 FALS, and 19 controls, whereas
the group with low VAPB expression level is composed of 24 SALS, 1 FALS,
and 2 controls. Fisher exact test was applied for each SNP, and a significant
difference of SNP rs6100067 was found (p 0.029).
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The detailed mechanism whereby VAPB participates in
UPR is still unclear. There is as yet no evidence showing a
direct interaction between VAP and IRE1 or XBP1 (65). How-
ever, the key amino acid residues involved in the trafficking of
lipid-associated proteins mediated by the FFAT (two pheny-
lalanines in an acidic tract) domain, such as CERT, OSBP, and
Nir (15, 17), are contained in a highly conserved 16-amino
acid region containing Thr46 (Fig. 1). It has been proposed
that this FFAT binding domain coincides with the domain
necessary for UPR activation via IRE1/XBP1 (14). Although
the P56S mutation would not be expected to affect FFAT
binding by itself (66), it still prevents IRE1 activation (13). It
was recently demonstrated that P56S obstructs FFAT binding
through enhancing VAPB oligomerization and thus decreases
accessibility to the VAPB binding domain (67). Therefore, the
inability of mutant VAPB to activate IRE1/XBP1 could be a
result of the mutations per se or could be the effect of protein
conformational changes imparted by the mutation, as is the
case for FFAT binding.
This is the first study in which the activation of the PERK
pathway has been monitored in VAPB-expressing cells, and
no significant effect of VAPB and VAPB mutations was de-
tected on the level of phosphorylated eIF2. However, we
found that high levels of phosphorylated eIF2 could be de-
tected 30 min to 2 h after thapsigargin treatment in NSC-34
cells and thereafter decreased to undetectable levels at 6 h,
suggesting that the phosphorylation of eIF2 is a rapid and
short term response that is then switched off upon the pro-
longed stressed condition. Therefore, we cannot exclude the
possibility that VAPB mutations may have rapid and transient
effects on the PERK pathway.
We have also shown that the expression of T46I-VAPB in
NSC-34 cells or T48I-DVAP in flies causes cell death without
any further challenge. An earlier report did show that P56S-
VAPB reduced cell viability in NSC-34 cells but only after
thapsigargin treatment (14). This difference may reflect the
fact that we are using permanent expression systems in vitro
and in vivo.
Non-cell-autonomous Effect Caused byMutant VAPB—
Emerging evidence indicates that the pathogenesis of many
neurodegenerative diseases including ALS, involves a non-
cell-autonomous process, but the mechanism mediating the
transfer of toxicity between cells is still unclear (1). Interest-
ingly, chromogranin-associated mutant SOD1 is secreted into
the extracellular milieu and induces microgliosis and neuro-
nal cell death (38, 39). Here we report that the co-culture of
WT- and T46I-VAPB-expressing cells results in much greater
cell death compared with T46I alone. This observation, to-
gether with the finding that untransfected cells cultured with
mutant VAPB transfected cells are more likely to contain
ubiquitinated aggregates than controls, suggests that mutant
VAPB-expressing cells are able to affect neighboring cells
that, although not producing the mutant protein themselves,
become stressed and eventually undergo cell death. Recent
findings have drawn attention to features of amyloid  and 
pathology in Alzheimer disease that are common to prion
disease, whereby an abnormal protein causes propagation of
protein misfolding between cells (for a review, see Ref. 68).
Such propagation may also occur following transfer from one
cell to the next by exocytotic release followed by neuronal
uptake, which may also be relevant to non-cell-autonomous
processes occurring in ALS.
In Drosophila, the N-terminal MSP domain of DVAP is
secreted and may act as a ligand of the Eph receptor, and the
P58S mutation in DVAP, equivalent to the human P56S mu-
tation in VAPB, inhibits the ability of the WT protein to be
secreted (40, 69). However, because we have been unable to
recover any VAPB fragments from the culture medium, it is
still undetermined whether the non-cell-autonomous effect is
caused by VAPB directly or by the release of other factors
triggered by VAPB. It is possible that mutant VAPB is re-
leased within exosomes, as has previously been shown for
-synuclein (70), where the authors suggested that this was a
potential process involved in Parkinson disease and other
neurodegenerative conditions.
Fly Model Expressing Mutant VAPB—The effect of the
newly identified mutation on cellular processes known to play
a role in neurodegeneration, such as UPR, accumulation of
ubiquitinated aggregates, and cell death, were studied in cell
lines. In a parallel and complementary approach, we used the
Drosophilamodel system to assess in vivo effects on relevant
ALS mechanisms. More specifically, the contributions of dif-
ferent tissues and systems (peripheral motor system, muscle,
and central nervous system) to the pathogenic effects induced
by the novel mutation were investigated in our Drosophila
model.
Previous studies have established Drosophila as a suitable
model system to study VAP-induced ALS. In particular, a
wealth of experimental evidence indicates that human VAPB
and DVAP are functionally interchangeable both in loss-of-
function and overexpression paradigms. First, many of the
fundamental biochemical properties of human VAPB, includ-
ing its ability to oligomerize and to interact with lipid-binding
FIGURE 11. Cellular disturbances triggered bymutant VAPB. In this
study, we demonstrated (highlighted in boldface type) that the expression of
ALS-linked mutant VAPB triggers VAPB protein aggregation as well as wild
type protein redistribution. As a consequence, structure and function of ER
are disrupted, which, together with the inability to activate the unfolded
protein-responsive pathway, IRE1/XBP1, leads to potentiation of ER stress,
the accumulation of ubiquitinated aggregates, and, eventually, cell death.
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proteins, are conserved in DVAP (21, 71). Second, transgenic
expression of DVAP carrying the ALS-causing mutation reca-
pitulates many of hallmarks of the human disease (21, 40, 41)
(this work). Furthermore, expression of human VAPB in a
mutant background for DVAP fully rescues the lethality and
the morphological and the electrophysiological phenotypes
associated with DVAP loss-of-function mutations (21, 40).
Taken together, these results strongly indicate that Drosoph-
ila is an excellent model organism to investigate both the WT
function of VAP proteins and their role in ALS pathogenesis.
Expression of T48I-DVAP throughout the nervous system
in Drosophila is lethal, and it causes premature death. To in-
vestigate the pathogenic mechanisms in more detail, we ana-
lyzed the effect of transgenic expression of the mutant allele
in particular areas of the nervous system. We have shown that
expression of T48I-DVP in neurons of the larval motor sys-
tem leads to accumulation of intracellular aggregates, and
targeted expression into the eye causes cell degeneration. Fur-
thermore, expression of the mutant allele depletes the WT
protein from its normal localization and recruits it into the
aggregates. As already shown for the P56S mutation (e.g. see
Ref. 35), this observation is consistent with the hypothesis
that the pathogenic allele causes a loss-of-function of WT
VAP by a dominant negative mechanism.
Dramatic ER restructuring has been reported in cell culture
systems expressing P56S-VAP allele (72). Furthermore struc-
tural abnormalities in the ER characterized by ER fragmenta-
tion and Golgi cisternal dilation have been reported in motor
neurons of patients affected by sporadic ALS (50). To test
whether this is also the case for the novel identified mutation,
we analyzed the ER structure in larval neurons expressing
T48I-DVAP. We found that the ER in these transgenic ani-
mals appears fragmented, supporting the hypothesis that
structural alterations of the ER are a consistent hallmark of
ALS and a possible cause of motor neuron degeneration. Fi-
nally, these neuropathological features, together with the up-
regulation and accumulation of chaperone proteins in clus-
ters, indicate a gradual overwhelming of the neuronal capacity
to properly handle the pathogenic DVAPs and identify cellu-
lar processes that are likely to be crucial for ALS pathogenesis.
Heat shock protein induction has been reported in a mouse
model with widespread mutant SOD1 expression (52), with
chaperones being found co-localized with SOD1 inclusions in
motor neurons (52–54). The fact that chaperones do not
overlap with DVAP-immunoreactive aggregates is an interest-
ing and distinct feature of fly models for motor neuron dis-
eases when compared with mouse models for the same dis-
ease (73). A similar result has been reported for the
expression of the pathogenic version of SOD1 in Drosophila,
in which a chaperone response was not present in neurons
but in a subset of surrounding glial cells (74).
Although the presence of inclusions suggests an over-
whelming of the neuronal capacity to properly handle the ac-
cumulation of the pathogenic protein, the lack of co-localiza-
tion of these aggregates with Hsp70 suggests that Hsp70
induction may reflect its cytoprotective effect in regulating
other pathways, such as autophagy and apoptosis.
The conventional belief that ALS is exclusively a motor
neuron disorder has been recently challenged by the fact that
the disease is associated with a broad range of neuropsycho-
logical and behavioral deficits (69) and affects non-neuronal
tissues, such as muscle, that may exacerbate the disease (1). In
support of this concept, we showed that expression of T48I-
DVAP in muscle is sufficient to induce the accumulation of
large intracellular aggregates of the mutant protein. This
would, in turn, trigger a local stress response, as occurs in mo-
tor neurons, which is characterized by sarcotubular fragmen-
tation and up-regulation of HSP70. The results of this study
show that muscle expression of the mutant protein can in-
duce muscle stress and dysfunction independently from the
consequences of motor neuron degeneration.
Effect of T46I-VAP on Lipid Dysfunction in ALS—VAP pro-
teins interact with lipid-binding proteins, such as CERT (17–
19, 66), a ceramide transfer protein required for sphingolipid
synthesis (75). Interestingly, the Thr46 residue is located in a
conserved core of VAP responsible for binding the FFATmotif
and is essential for binding CERT (16, 66). Therefore, it is very
likely that the T46I mutation affects the ability of VAP to interact
with these proteins and as a consequence causes dysfunction in
lipid metabolism. Furthermore, flies lacking CERT activity ex-
hibit increased sensitivity to oxidative damage, motor disabilities,
and reduced life span (76), and inactivation of CERT inmice
causes dilation of the ER, induction of UPR, and impairedmito-
chondrial activity (77), all of whichmay play a crucial role in ALS
pathogenesis. Indeed, ALS patients carrying the P56S-VAPB
mutation exhibit hyperlipidemia and increased cholesterol and
triglyceride levels (6), andmore recent studies have revealed that
ALS patients are more likely to show evidence of hyperlipidemia
compared with controls (78). To conclude, data reported here
and in earlier studies suggest that a correlationmay exist be-
tween dysfunction in lipid metabolism and ALS pathogenesis,
which warrants further investigation.
In summary, based on the data presented here and from
earlier studies, we propose a model for the effects of ALS-
associated VAPB mutations and define putative pathogenic
pathways (Fig. 11). As we have shown here, mutant VAPB has
a profound effect on the IRE1 component of UPR, abolishing
the ability of VAPB to activate this pathway and thereby im-
pairing induction of ER chaperones and ERAD activity. This
in turn prolongs the effects of ER stress. Accumulation of
ubiquitinated protein aggregates reflects this abnormality and
promotes cell death. This pathway would be augmented by
aggregation of mutant VAPB and ER fragmentation. In addi-
tion, recruitment of VAPA and wild type VAPB to mutant
VAPB dimers could cause dysregulation of lipid trafficking
and further reduce cell viability.
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